Crispr Therapeutics AG (CRSP)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Crispr Therapeutics AG.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 48.00 $ — 11% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 80.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 28
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -4.86 | -6.37 – -3.35 | 42 | 25.0% | 19 |
| 12/31/2027 | -3.89 | -6.23 – -0.68 | 163 | 19.9% | 19 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.10 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.44 | -139.70 | 35 | -82.50 | -106.60 | -50 | -50 |
| 2025: Q1 | -1.58 | – | 1 | 71.60 | -15,722.10 | -54 | -54 |
| 2025: Q2 | -2.40 | – | 1 | 72.50 | -23,379.90 | -114 | -114 |
| 2025: Q3 | -1.17 | – | 1 | 47.70 | -11,973.10 | -85 | -85 |
| 2025: Q4 | -1.45 | – | 1 | -97.50 | -15,117.20 | -93 | -93 |
| 2026: Q1 | -1.28 | – | 2 | 68.60 | -8,431.50 | -109 | -109 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -68 | -23 | -1.89 | -55 | 233 | 345 |
| 2017 | 41 | -65 | -68 | -1.71 | -70 | 188 | 271 |
| 2018 | 3 | -159 | -165 | -3.44 | -96 | 392 | 489 |
| 2019 | 290 | 47 | 67 | 1.17 | 57 | 939 | 1,067 |
| 2020 | 1 | -354 | -349 | -5.29 | -238 | 1,664 | 1,828 |
| 2021 | 913 | 374 | 378 | 4.70 | 539 | 2,399 | 2,752 |
| 2022 | 0 | -673 | -650 | -8.36 | -496 | 1,875 | 2,243 |
| 2023 | 370 | -223 | -154 | -1.94 | -260 | 1,883 | 2,230 |
| 2024 | 35 | -467 | -366 | -4.34 | -143 | 1,932 | 2,242 |
| 2025 | 4 | -568 | -582 | -6.47 | -345 | 1,922 | 2,265 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
CRISPR Therapeutics AG, ein Gen-Editing-Unternehmen, konzentriert sich auf die Entwicklung genbasierter Medikamente für schwere Erkrankungen mithilfe ihrer CRISPR/Cas9-Plattform. CRISPR/Cas9 ist eine Technologie zur Gen…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 393 |
| Headquarters | Zug, Switzerland |
| Address | Baarerstrasse 14, 6300 Zug, Switzerland |
| Phone | 41 41 561 32 77 |
| Website | crisprtx.com |
| IPO Date | 19. Oct 2016 |
| ISIN | CH0334081137 |
| Stock Split | 333333:100000 on 07/19/2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Samarth Kulkarni Ph.D. | CEO & Chairman | 1978 |
| Raju Yashaswi Prasad Ph.D. | Chief Financial Officer | 1984 |
| James R. Kasinger J.D. | General Counsel & Secretary | 1972 |
| Naimish Patel C.M., M.D. | Chief Medical Officer | 1972 |
| Shaun Foy CFA | Co-Founder | – |
| Emmanuelle Marie Charpentier Ph.D. | Co-Founder & Scientific Advisory Board Member | – |
| Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | – |
| Chad A. Cowan Ph.D. | Scientific Founder | 1972 |
| Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | 1965 |
| Daniel G. Anderson Ph.D. | Scientific Founder & Advisory Board Member | 1970 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.